(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Health care stocks were mixed pre-bell Monday. The Health Care SPDR (XLV) was up 0.12%, and the iShares NASDAQ Biotechnology Index (IBB) was recently 0.20%...
US stocks were set for narrow gains Monday, extending previous session's gains after an inflation expectation gauge showed a slight easing. Dow Jones...
Epizyme (EPZM) has an average rating of buy and price targets ranging from $0.60 to $8, according to analysts polled by Capital IQ. (MT Newswires covers...
| Address | 400 Technology Square Cambridge, Massachusetts 02139 |
| Phone | +1.617.229.5872 |
| Number of Employees | 124 |
| Recent SEC Filing | 06/28/2022 SC 13D/A |
| President, Chief Executive Officer, CFO & Director | Grant C. Bogle |
| Chief Operating Officer | Jerald Korn |
| Chief Scientific Officer & Executive VP | Jeffery L. Kutok |
| Secretary, Senior Vice President & General Counsel | John F. Weidenbruch |
| Price Open | $1.46 |
| Previous Close | $1.47 |
| 52 Week Range | $0.41 - 8.59 |
| Market Capitalization | $243.2 M |
| Shares Outstanding | 164.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/08/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$2.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $21.7 M |
| Net Profit Margin | -614.08% |
| Return on Equity | -1,287.29% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
